July 9, 2013: The New York Times , Gina Kolata, “Rare mutation ignites race for cholesterol drug”
Despite major gains over the past half-century, heart disease remains the leading killer of Americans, causing nearly 600,000 deaths a year. Statins, the cholesterol-lowering drugs that went on the market in 1987, were a huge breakthrough, but far from a panacea.
The companies and many heart researchers hope they are closing in on a blockbuster, buoyed by success with preliminary studies. But Dr. Gibbons cautioned that critical large-scale studies that would tell whether the drugs actually prevent heart attacks and deaths are only starting. “That will show if they are a game changer,” he said.
May 12, 2013: The New York Times , Gina Kolata, “Seeking clues to heart disease in DNA of an unlucky family”
“Risk factors are part of the canon now in medicine,” said Dr. Gary H. Gibbons, the director of the National Heart, Lung, and Blood Institute. “We use them every day. Still, people arrive at the hospital every day with heart attacks.”
March 19, 2013: Princeton Alumni Weekly , Jocelyn Kaiser, “Shaping biomedical research”
Offered the top job at the NHLBI last year, Gary Gibbons ’78 was attracted by the chance to steer an agency with a $3 billion budget for research on heart, lung, and blood disorders. But that wasn’t all. Gibbons, a cardiologist and scientist, also saw the position as an opportunity to address what he calls an “egregious” problem: a dearth of African-American scientists in biomedical research.
February 12, 2013: News 12 Long Island , Elisa DiStefano, “Video interview with Dr. Gary Gibbons”
"It's critical that we reach women to enhance their awareness that heart disease is their number-one killer, and encourage them to have dialogues with their doctor and become empowered to take action to reduce their risk of heart disease."
January 30, 2013: Nature , Cassandra Willyard, “Pathology: At the heart of the problem”
These and other studies suggests that "we still need to learn more about HDL biology and recognize that it's a complex molecule in order to be sure that we develop the best therapeutic strategy," says Gary Gibbons, director of the US National Heart, Lung, and Blood Institute in Bethesda, Maryland.